Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
11(46%)
Results Posted
0%(0 trials)
Terminated
1(4%)

Phase Distribution

Ph not_applicable
13
54%
Ph phase_2
3
13%
Ph phase_3
8
33%

Phase Distribution

0

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution24 total trials
Phase 2Efficacy & side effects
3(12.5%)
Phase 3Large-scale testing
8(33.3%)
N/ANon-phased studies
13(54.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

11

trials recruiting

Total Trials

24

all time

Status Distribution
Active(13)
Completed(4)
Terminated(1)
Other(6)

Detailed Status

Recruiting10
unknown6
Completed4
Not yet recruiting2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
11
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (12.5%)
Phase 38 (33.3%)
N/A13 (54.2%)

Trials by Status

active_not_recruiting14%
not_yet_recruiting28%
recruiting1042%
unknown625%
completed417%
terminated14%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT06745024Phase 3

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

Active Not Recruiting
NCT07566156Phase 3

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

Not Yet Recruiting
NCT06980259Not Applicable

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma

Recruiting
NCT07455331Phase 2

Flash Radiotherapy for Skin Cancer

Not Yet Recruiting
NCT07188532Not Applicable

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

Recruiting
NCT06607406Not Applicable

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

Recruiting
NCT07164885Not Applicable

RAPART in Locally Advanced Non-small Cell Lung Cancer Patients

Recruiting
NCT06596954Not Applicable

Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

Recruiting
NCT05439278Phase 3

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Recruiting
NCT06928584Phase 2

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Recruiting
NCT06641635Phase 3

Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer

Recruiting
NCT01504815Phase 3

Adaptive Radiation Treatment for Head and Neck Cancer

Completed
NCT06313450Not Applicable

De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT03899376Not Applicable

A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT

Unknown
NCT01429493Phase 2

Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases

Completed
NCT03374592Not Applicable

Volumetric Intensity Modulated Arc Therapy vs. Conventional Radiotherapy for Cancer Pain

Completed
NCT03829553Phase 3

Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment

Recruiting
NCT02407795Not Applicable

Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases

Terminated
NCT02752126Not Applicable

A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus

Completed
NCT04015531Not Applicable

Hypofractionated Versus Conventional Fractionation Radiotherapy

Unknown

Drug Details

Intervention Type
RADIATION
Total Trials
24